Join us for this live Clinical OMICs webinar, sponsored by Natera, for a dynamic discussion with our esteemed guests Dr. Gregory Botta from UC San Diego and Dr. Angel Rodriguez from Natera, who will review the value of a tumor informed approach to optimize patient management in the adjuvant treatment setting.
In this inaugural Clinical OMICs Keynote webinar, we are proud to host two renowned leaders in the field of genomic medicine, Drs Stephen Kingsmore and Robert Green, who will discuss their pioneering work in the field of newborn genome sequencing and analysis.
In this inaugural episode of CLINICAL OMICs Live, sponsored by Fabric Genomics, we welcome Dr. Euan Ashley, a leading medical geneticist at Stanford University, to discuss his new book, The Genome Odyssey. A cardiologist by training, Dr. Ashley has been at the leading edge of genomic medicine for more than a decade. He led the team that conducted arguably the first in-depth interpretation of a full genome sequence. He’s a co-founder of Personalis and other companies.
In this Keynote Webinar, sponsored by Illumina, two leading researchers will show how genomic technologies are tackling the COVID-19 pandemic—Alex Greninger, MD, PhD, (University of Washington School of Medicine) and Darrell Dinwiddie PhD, (University of New Mexico Health Sciences Center).
In this Clinical OMICs webinar, sponsored by Bio-Rad, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for treatment of COVID-19.
In this Clinical OMICs webinar, sponsored by Illumina, we will discover how combining molecular and immune profiling's power to drive molecular-based testing is improving stratification methods and patient outcomes. Additionally, our expert panelist will showcase the impact of a scalable, comprehensive assay, and infrastructure in the context of drug development.
In this exciting new webinar, sponsored by Ultivue, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials.
The promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.
Sponsor: Bionano Genomics
Sponsored content brought to you by What if every patient’s oncologist or lab testing personnel had access to an online digital encyclopedia of cancer mutations,...